India’s Emcure Pharmaceuticals aims to raise $400-500 million from an initial public offering planned for next year, two sources said, reviving listing plans the drugmaker shelved in early 2022 as the Ukraine war roiled global markets.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
